Published by Josh White on 5th June 2025
(Sharecast News) - Hutchmed China and Innovent Biologics announced on Thursday that China's National Medical Products Administration had accepted a new drug application for a combination therapy using fruquintinib and sintilimab to treat advanced renal cell carcinoma in patients who have failed prior tyrosine kinase inhibitor treatment.